JaLCDOI 10.18926/AMO/54600
フルテキストURL 70_5_397.pdf
著者 Akagi, Satoshi| Nakamura, Kazufumi| Akagi, Teiji| Nakagawa, Koji| Takaya, Yoichi| Sarashina, Toshihiro| Ejiri, Kentaro| Ito, Hiroshi|
抄録 A treatment strategy for patients with pulmonary hypertension (PH) and atrial septal defect (ASD) remains unclear. This study was designed to evaluate the effects of initial repair of ASD followed by treatment with PH-specific drugs in patients with PH and ASD. Eligible patients receive transcatheter ASD closure followed by treatment with bosentan and sildenafil. Right heart catheterization is performed at baseline and at 12, 24 and 48 weeks. The primary endpoint is change in pulmonary artery pressure and pulmonary vascular resistance from baseline to follow-up. This study should provide valuable information to establish a therapeutic strategy for PH and ASD.
キーワード pulmonary hypertension atrial septal defect repair and treat transcatheter closure
Amo Type Clinical Study Protocols
発行日 2016-10
出版物タイトル Acta Medica Okayama
70巻
5号
出版者 Okayama University Medical School
開始ページ 397
終了ページ 400
ISSN 0386-300X
NCID AA00508441
資料タイプ 学術雑誌論文
言語 English
著作権者 CopyrightⒸ 2016 by Okayama University Medical School
論文のバージョン publisher
査読 有り
PubMed ID 27777434
Web of Sience KeyUT 000388098700011
JaLCDOI 10.18926/AMO/53519
フルテキストURL 69_3_129.pdf
著者 Akagi, Satoshi| Nakamura, Kazufumi| Matsubara, Hiromi| Ogawa, Aiko| Sarashina, Toshihiro| Ejiri, Kentaro| Ito, Hiroshi|
抄録 Pulmonary arterial hypertension (PAH) is characterized by elevation of pulmonary artery pressure caused by pulmonary vasoconstriction and vascular remodeling, which leads to right heart failure and death. Epoprostenol (prostaglandin I2) has a potent short-acting vasodilator property, and intravenous continuous epoprostenol is therefore used for treatment of PAH. Here we review evidence for the usefulness of intravenous continuous epoprostenol therapy in patients with PAH. Epoprostenol therapy is effective in idiopathic PAH patients and in patients with PAH associated with connective tissue disease, portal hypertension or congenital heart diseases, but it is not effective in patients with pulmonary veno-occlusive disease or pulmonary capillary hemangiomatosis. High-dose epoprostenol therapy markedly improved hemodynamics in some patients with PAH, possibly due to reverse remodeling of pulmonary arteries. This therapy has several side effects and complications such as headache, hypotension and catheter-related infections. Intravenous continuous epoprostenol is an effective treatment, but there are still some problems to be resolved.
キーワード pulmonary arterial hypertension epoprostenol high-dose complications side effects
Amo Type Review
発行日 2015-06
出版物タイトル Acta Medica Okayama
69巻
3号
出版者 Okayama University Medical School
開始ページ 129
終了ページ 136
ISSN 0386-300X
NCID AA00508441
資料タイプ 学術雑誌論文
言語 English
著作権者 CopyrightⒸ 2015 by Okayama University Medical School
論文のバージョン publisher
査読 有り
PubMed ID 26101188
Web of Sience KeyUT 000356903000001
タイトル(別表記) The 2013 Incentive Award of the Okayama Medical Association in Cardiovascular and Pulmonary Research (2013 Sunada Prize)
フルテキストURL 126_195.pdf
著者 赤木 達|
抄録 受賞対象論文: Akagi S, Nakamura K, Matsubara H, Kusano KF, Kataoka N, Oto T, Miyaji K, Miura A, Ogawa A, Yoshida M, Ueda-Ishibashi H, Yutani C, Ito H:Prostaglandin I2 induces apoptosis via upregulation of Fas ligand in pulmonary artery smooth muscle cells from patients with idiopathic pulmonary arterial hypertension. Int J Cardiol (2013) 165, 499-505.
備考 平成25年度岡山医学会賞紹介記事 (The 2013 Okayama Medical Association Award)
出版物タイトル 岡山医学会雑誌
発行日 2014-12-01
126巻
3号
出版者 岡山医学会
出版者(別表記) Okayama Medical Association
開始ページ 195
終了ページ 197
ISSN 0030-1558
NCID AN00032489
資料タイプ 学術雑誌論文
言語 Japanese
著作権者 Copyright (c) 2014 岡山医学会
論文のバージョン publisher
査読 有り
DOI 10.4044/joma.126.195
NAID 130004903242
Sort Key 3
Eprints Journal Name joma
参考文献 1) McLaughlin VV, Shillington A, Rich S : Survival in primary pulmonary hypertension : The impact of epoprostenol therapy. Circulation (2002) 106, 1477-1482. 2) Sitbon O, Humbert M, Nunes H, Parent F, Garcia G, Herve P, Rainisio M, Simonneau G : Long-term intravenous epoprostenol infusion in primary pulmonary hypertension : Prognostic factors and survival. J Am Coll Cardiol (2002) 40, 780-788. 3) McLaughlin VV, Genthner DE, Panella MM, Rich S : Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N Engl J Med (1998) 338, 273-277. 4) Akagi S, Nakamura K, Miyaji K, Ogawa A, Kusano KF, Ito H, Matsubara H : Marked hemodynamic improvements by high-dose epoprostenol therapy in patients with idiopathic pulmonary arterial hypertension. Circ J (2010) 741, 2200-2205.